On Monday, Qiagen NV (NYSE:QGEN) announced at its Capital Markets Day a comprehensive strategy aimed at delivering solid and profitable growth through 2028. The company targets a 7% compound annual sales growth at constant exchange rates (CER) by 2028. At the event, the German molecular diagnostics firm announced its plans to return at least $1 billion to shareholders from 2024 to 2028, barring value-creating M&A opportunities while maintaining high levels of organic business investments. Key strategic pillars for growth include: QIAcuity Digital PCR: Plans include tripling the sales team to drive adoption, launching over 100 new assays, and seeking U.S. regulatory clearance for clinical use in 2024. A companion diagnostic agreement with an undisclosed pharma partner was also signed. QIAstat-Dx: A new panel for syndromic ...